Pharm'Up 
The FDA has officially expanded the approval of the intravenous (IV) formulation of tocilizumab-anoh (Avtozma; Celltrion Inc), a biosimilar to the reference product Actemra IV (tocilizumab; Roche, Genentech). This expanded indication now includes the treatment of cytokine release syndrome (CRS) in adult and pediatric patients aged 2 years and older, bringing its full range of indications into complete alignment with its reference product.
Understanding Cytokine Release Syndrome (CRS)
Cytokine release syndrome is a potentially life-threatening systemic inflammatory condition. It occurs when the body’s immune system, typically in response to infections or specific immunotherapies like CAR T-cell therapy, releases an excessive amount of pro-inflammatory cytokines into the bloodstream. This “cytokine storm” can lead to a wide spectrum of symptoms, ranging from mild flu-like signs such as fever and fatigue to severe, life-threatening organ dysfunction affecting the heart, lungs, and kidneys.
Treatment for CRS is highly variable and depends on the severity of the symptoms. It can include supportive care like IV fluids, fever-reducing medications, and oxygen, as well as more aggressive interventions such as mechanical ventilation and blood transfusions. The availability of effective therapeutic agents that can directly modulate this inflammatory response is crucial for improving patient outcomes.
Mechanism of Action and Clinical Evidence
Tocilizumab-anoh is a recombinant humanized monoclonal antibody. Its therapeutic effect is achieved by specifically binding to and blocking the interleukin-6 (IL-6) receptor. IL-6 is a key pro-inflammatory cytokine that plays a central role in the pathophysiology of CRS. By inhibiting the action of IL-6, tocilizumab-anoh helps to mitigate the excessive inflammatory cascade, thereby alleviating the symptoms of CRS.
The expanded approval was supported by a Phase 3 clinical trial that demonstrated the biosimilar’s equivalence to the reference product, Actemra, in terms of efficacy, pharmacokinetics, safety, and immunogenicity. This trial involved patients with moderate to severe rheumatoid arthritis (RA) and showed similar improvements across all measured disease activity outcomes. The data provided the necessary confidence for the FDA to grant full indication alignment for tocilizumab-anoh, including its use for CRS.
Impact on Patient Access and Therapeutic Options
Thomas Nusbickel, Chief Commercial Officer at Celltrion USA, stated that this FDA approval is a significant step forward in making a safe and effective therapy for CRS more widely accessible. As a biosimilar, tocilizumab-anoh is expected to offer a more affordable treatment option, potentially increasing its availability and reducing healthcare costs. This expanded approval enhances the therapeutic landscape for CRS and other inflammatory conditions, ensuring that healthcare providers and patients have a broader range of high-quality biologic treatment options.
About the Author
